SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Medical - Healthcare >

InVivo Therapeutics Holdings Corp (NVIV)

Add NVIV Price Alert      Hide Sticky   Hide Intro
Moderator: TheHound
Search This Board: 
Last Post: 4/24/2017 4:39:08 PM - Followers: 189 - Board type: Free - Posts Today: 6

About InVivo Therapeutics 

InVivo Therapeutics Corporation is a Cambridge, MA based medical device company founded to develop and commercialize groundbreaking technologies for the treatment of spinal cord injuries (SCI).Currently, there are no treatment options for SCI patients to successfully restore function following a spinal cord injury. Existing treatments consist of a collection of approaches that only focus on symptoms of SCI, such as decompression and mechanical stabilization of the spinal cord, rather than on the underlying pathology. InVivo intends to develop its novel Neuro-Spinal Scaffold to treat acute SCI and Neuro-Scaffold Plus Stem Cells to treat chronic SCI. - See more at:

In the Spotlight

October 23, 2015 InVivo Therapeutics Reports Significant Improvement of First Patient Implanted with Neuro-Spinal Scaffold™

October 19, 2015   InVivo Therapeutics Announces Expansion of Number of Patients in Pilot Study

October 1, 2015 Early Promise for a New Paralysis Treatment

September 9, 2015 InVivo Therapeutics Announces Mount Sinai Hospital in New York City as New Site for Neuro-Spinal Scaffold™ Clinical Trial

September 8, 2015 InVivo Therapeutics Announces Enrollment of Fifth Patient in Pilot Spinal Cord Injury Study

August 20, 2015 InVivo Therapeutics Announces Enrollment of Fourth Patient in Pilot Spinal Cord Injury Trial

August 13, 2015 InVivo Therapeutics’ CEO and Chairman, Mark Perrin, Interviewed by Maria Bartiromo on FOX Business Network’s “Mornings with Maria”

July 6, 2015 InVivo Therapeutics Reports Significant Improvement of Second and Third Patients Implanted with Neuro-Spinal Scaffold

June 22, 2015 InVivo Therapeutics Receives Notice of Allowance on Patent Covering Broader Compositions for Neuro-Spinal Scaffold and Neuro-Spinal Scaffold Plus Stem Cells

June 5, 2015- InVivo Therapeutics Announces Enrollment of Third Patient in Pilot Spinal Cord Injury Trial

April 16, 2015InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) to Ring The Nasdaq Stock Market Opening Bell

April 8, 2015 - InVivo Therapeutics Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to NASDAQ

March 26, 2015 - InVivo Therapeutics Announces Reopening of Enrollment for Subjects Three through Five for Anticipated Completion of Ongoing Pilot Trial

March 11, 2015 - InVivo Therapeutics Reports 2014 Year End Financial Results and Business Update

February 23, 2015 - InVivo Therapeutics Announces Froedtert & the Medical College of Wisconsin as New Clinical Trial Site for Neuro-Spinal Scaffold

February 9, 2015 - InVivo Therapeutics Appoints Lorianne Masuoka, MD as Chief Medical Officer

February 5, 2015 - InVivo Therapeutics Announces CEO Mark Perrin Named Chairman of the Board

February 2, 2015 - Video - Second Implantation of InVivo Therapeutics Neuro-Spinal Scaffold In Charlotte

January 22, 2015 - InVivo Therapeutics Announces Enrollment of Second Subject in Pilot Spinal Cord Injury Trial

January 21, 2015 - Zacks Small Cap Research Report- $3.25 Price Target

January 21, 2015 - Jordan's 1st Patient Video

January 21, 2015 - InVivo Therapeutics Reports Three-Month Update of First Acute Spinal Cord Injury Subject Implanted with Neuro-Spinal Scaffold

December 18, 2014 - Microcap - NVIV Research Report **A MUST READ**

December 16, 2014 - InVivo Therapeutics Announces FDA Approval to Expedite Enrollment for Ongoing Pilot Trial

November 11, 2014 - Scottsdale man hopes to walk again after groundbreaking surgery

October 29, 2014 - InVivo Therapeutics Receives FDA Approval to Broaden Inclusion Criteria and Add 14 Additional Sites (20 Total) for Ongoing Pilot Trial

October 15, 2014 - InVivo Therapeutics Announces First Subject Enrolled in Pilot Spinal Cord Injury Trial

April 28, 2014 - InVivo Therapeutics Initiates First Clinical Trial of Neuro-Spinal Scaffold


Ongoing Human Trials:
SEC Filings:
Recent News:
Share Structure:
Investor Presentation:



All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
NVIV News: Statement of Changes in Beneficial Ownership (4) 04/20/2017 06:20:25 PM
NVIV News: InVivo Therapeutics Announces Oral Presentations at the 2017 American Spinal Injury Association Annual Scientific Meeting 04/20/2017 08:00:00 AM
NVIV News: Current Report Filing (8-k) 04/13/2017 08:36:12 AM
NVIV News: Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) 04/13/2017 06:03:09 AM
NVIV News: InVivo Therapeutics Announces New Site for INSPIRE Study 04/10/2017 08:00:00 AM
#5834   I already took into account they wouldn't take Pemmanuel 04/24/17 04:39:08 PM
#5833   May, could, should, possibly, perhaps, is a possibility. DDobserver 04/24/17 01:46:09 PM
#5832   Well.. think some of those things considered... now invest 04/24/17 01:15:44 PM
#5831   17 months of cash is a big misconception BioBull1 04/24/17 10:34:54 AM
#5830   Lots of old price targets and likely will BioBull1 04/24/17 10:27:22 AM
#5829   The company is currently at a 1.4MM per Pemmanuel 04/24/17 10:15:18 AM
#5828   I do not think they are fundamentally different. DDobserver 04/21/17 05:33:32 PM
#5827   Your reply seems disingenuous and definitely hypocritical in Pemmanuel 04/21/17 04:21:17 PM
#5826   Thanks for the clarity of 50mm shares authorized. DDobserver 04/21/17 12:31:35 PM
#5825   There are currently 50MM shares authorized. Current outstanding Pemmanuel 04/21/17 11:06:07 AM
#5824   HOUND .2904 cents per share DDobserver 04/21/17 10:33:44 AM
#5823   I added some a couple of days ago... now invest 04/20/17 02:07:12 PM
#5822   Regardless if it is a vote or a DDobserver 04/20/17 09:31:07 AM
#5821   That is patently false. The vote is a Pemmanuel 04/20/17 08:13:03 AM
#5820   I totally agree ronala. NVIV is entering a Pemmanuel 04/20/17 12:22:35 AM
#5818   They are on fast track via HDE. NVIV Pemmanuel 04/19/17 11:59:09 PM
#5815   yeah. The 8K did't give enough information and Devo33 04/18/17 01:49:08 PM
#5814   Several of my small cap BIOs had 3-7% now invest 04/18/17 08:44:06 AM
#5813   Dark pools, Swaps, avoidance of reality, hype, etc. DDobserver 04/18/17 12:09:41 AM
#5812   Anyone has explanation for today's 16% pop? The Lawman 04/17/17 11:03:02 PM
#5811   Something might be brewing with this 16% pop mastiffsforlife 04/17/17 04:03:25 PM
#5810   I have been buying for the last couple now invest 04/17/17 03:47:36 PM
#5809   Where do I get dilution from. DDobserver 04/17/17 02:35:20 PM
#5808   where do you get potential dilution from? ronala 04/17/17 01:50:42 PM
#5807   DILUTION of EQUITY, TWO KEY EMPLOYEES LEFT, and DDobserver 04/14/17 06:43:45 AM
#5806   And supposedly we were on fast track for attilathehunt 04/13/17 06:37:39 PM
#5805   Didn't read the new CP yet but I mastiffsforlife 04/13/17 06:35:11 PM
#5804   Wow! They will do anything to extend attilathehunt 04/13/17 01:39:12 PM
#5803   me too! pennies to bills ! pennies to TheHound 04/06/17 10:40:47 AM
#5802   I like to buy all my shares of scottsmith 04/06/17 09:35:18 AM
#5801   hoping for a buck! TheHound 04/06/17 09:25:44 AM
#5800   Bottom on this one is sub 2. scottsmith 04/06/17 09:05:03 AM
#5799   agree with both of you. BioBull1 04/05/17 04:45:39 PM
#5798   Agreed. They should rename it to Coric procedure. attilathehunt 04/05/17 09:14:25 AM
#5797   20+ sites able to enroll but somehow Dr. mastiffsforlife 04/05/17 08:13:37 AM
#5794   Rarely visit this board anymore. Still hold mastiffsforlife 04/03/17 05:50:10 PM
#5793   Nice exit package for the event of attilathehunt 03/31/17 04:31:57 PM
#5791   Great news for the patient!! 7 out of 11 attilathehunt 03/28/17 08:55:22 AM
#5790   here's more pieces. InVivo Therapeutics Announces Seventh Patient Conversion TheHound 03/28/17 08:24:42 AM
#5789   Do you have a link for your assertion? DDobserver 03/24/17 01:59:15 PM
#5788   read bionap, by Jason. another buy reco. ronala 03/24/17 01:15:14 PM
#5787   Looks like a good buying opportunity at these Halks1122 03/23/17 04:15:46 PM
#5786   Besides a broad negative view and concern with DDobserver 03/22/17 08:20:51 AM
#5785   More like a POS issue. scottsmith 03/21/17 05:02:56 PM
#5784   Buying opportunity Devo33 03/21/17 12:59:47 PM
#5783   it's a sector and broad market issue. TheHound 03/21/17 12:50:54 PM
#5782   Was today's news bad? What am I Johnny Penstock 03/21/17 12:25:38 PM
#5781   also, Thomson Reuters has a buy on nviv ronala 03/21/17 10:32:24 AM
#5780   $NVIV news ----> TheHound 03/20/17 10:18:25 AM
#5779   Ronala, I looked into these links you provided and DDobserver 03/18/17 05:10:23 AM